NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Register
ADVERTISEMENT
ADVERTISEMENT
An exploration of whether different joints have different treatment outcomes was the subject of a large scale observational study presented at the 2024 EULAR Congress in Vienna.
Arthritis affects various joints differently, despite systemic inflammatory cues. In people with rheumatoid arthritis, transcriptomic variances identified in synovial fibroblasts from various joint sites have been shown to translate into joint-specific phenotypes with distinct characteristics and responsiveness to cytokines. These findings suggest that different joints may potentially respond variably to specific immunosuppressive treatments.
To expand on this, Ciurea and colleagues set out to investigate whether joints at different anatomical locations in people with psoriatic arthritis (PsA) might respond differently to treatment with a tumour necrosis factor inhibitor (TNFi).
The research was based on real-life data from several European registries collaborating in the EuroSpA network–and over 1,700 PsA patients starting a first TNFi. The primary outcome was time to first resolution of joint swelling on an individual joint level based on the 28-joint count, assessed at baseline and at various time points over two years.
At baseline, the mean number of swollen and tender joints was 4.8 and 7.4, respectively, with a mean disease activity score using the C-reactive protein (DAS28-CRP) of 4.7. When looking at joints of the upper limb – with the proximal interphalangeal joint of the third digit (PIP3) as a reference – a significantly higher rate of resolution of joint swelling was observed for the elbow and the shoulder. In contrast, a lower rate of resolution of joint swelling was found for the wrist in relation to the PIP3 joint. However, there was no evidence for a difference in resolution of joint swelling in the knee as compared to the elbow.
The results suggest that the clinical response to a TNFi in PsA appears to depend on joint location – at least in terms of time to the first resolution of joint swelling.
This approach also indirectly identified those joints that were less likely to resolve despite TNFi treatment, suggesting that local factors might impact treatment effectiveness at specific joints – such as mechanical factors or specific synovial fibroblast phenotypes. This new work suggests a need for future analyses to explore whether joint-specific responses in PsA are associated with distinct therapeutic modes of action.
Reference: Ciurea A, et al. Differential joint-level responses to TNF inhibitors in psoriatic arthritis: A collaborative European observational cohort study. Presented at EULAR 2024; OP0034. Ann Rheum Dis 2024; doi: 10.1136/annrheumdis-2024-eular.2535
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
A new study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS),...
Recent developments in the understanding of MS pathogenesis have suggested new avenues for disease-modifying therapy; in...
ADVERTISEMENT
There is a lot of publicity given to the Volkswagen Golf, which is celebrating 50 years...
As older doctors retire, a new generation has arrived with different professional and personal priorities. Around...
Catherine Reily examines the growing pressures in laboratory medicine and the potential solutions,with a special focus...
The highlight of this year’s Irish Society for Rheumatology (ISR) Autumn Meeting was undoubtedly the...
ADVERTISEMENT
ADVERTISEMENT
Leave a Reply
You must be logged in to post a comment.